TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30509928

Group type: EXPERIMENTAL
Intervention: Total Physical Activity (PA)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Light Physical Activity (LPA)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Physical Activity (MVPA)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Sedentary Behavior (SB)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Boys vs Girls in LPA
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Boys vs Girls in MVPA
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Fat mass index and BMI z scores
Number of subjects: 600
Study: 28152465

Group type: EXPERIMENTAL
Intervention: MET plus oxytocin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 25393172

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) with financial incentives for abstinence; 4 weeks duration
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care (UC; cessation program)
Number of subjects: 146
Study: 24613024

Group type: EXPERIMENTAL
Intervention: Solomon technique (fetoscopic laser coagulation of the entire vascular equator)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Standard laser coagulation
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Solomon technique
Number of subjects: 274
Study: 22443837

Group type: EXPERIMENTAL
Intervention: Comprehensive microfinance intervention (matched savings accounts, financial management workshops, mentorship)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (traditional services: counseling and school supplies)
Number of subjects: 286
Study: 19923168

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180‐mg load, 90‐mg BID maintenance dose)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Clopidogrel (600‐mg load, 75‐mg/d maintenance dose)
Number of subjects: 123
Study: 17876889

Group type: EXPERIMENTAL
Intervention: Low-dose intermittent interferon (IFN) therapy (3 MIU of natural IFN‐alpha intramuscularly 3 times weekly for at least 48 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-dose intermittent interferon (IFN) therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-IFN group (historical controls)
Number of subjects: 32
Study: 16009829

Group type: COMPARATOR
Intervention: Latanoprost therapy alone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Latanoprost-timolol-fixed combination therapy
Number of subjects: 37
Study: 12774194

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 micro g p.o. b.i.d. for 14 days)
Number of subjects: 10
Study: 11307189

Group type: EXPERIMENTAL
Intervention: Rotation group (10 subjects) with clockwise rotation of the palatal plane
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Impaction group (13 subjects) with maxillary superior repositioning
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (11 adults) with skeletal Class III malocclusion without open bite
Number of subjects: 23
Study: 8966497

Group type: EXPERIMENTAL
Intervention: Menorest 50 mikrog/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Premarin 0.625 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Menorest 50 mikrog/day and Premarin 0.625 mg
Number of subjects: 32
Study: 1563807

Group type: EXPERIMENTAL
Intervention: Albendazole 10 mg/kg/day for four courses of 30 days with 15‐day drug‐free intervals
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mebendazole 50‐70 mg/kg/day continuously for between 6 and 24 months
Number of subjects: 25
Study: 6386490

Group type: EXPERIMENTAL
Intervention: UK‐38,485 50 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31208943

Group type: EXPERIMENTAL
Intervention: Second-generation TKIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-generation TKIs (favourable scenarios)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second-generation TKIs vs Imatinib
Number of subjects: 0
Study: 28753851

Group type: EXPERIMENTAL
Intervention: ODM-201 (1200-1800mg/d)
Number of subjects: 41
Study: 27282110

Group type: EXPERIMENTAL
Intervention: Autograft (gracilis and semitendinosus tendons)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hybrid graft (γ‐irradiated tibialis anterior tendon allograft and semitendinosus tendon autograft)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: γ‐irradiated allograft (tibialis anterior tendons)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 24666811

Group type: EXPERIMENTAL
Intervention: 12-week moderate-intensity, group aerobic exercise intervention (AE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Brief advice to exercise intervention (BA-E)
Number of subjects: 48
Study: 22673453

Group type: EXPERIMENTAL
Intervention: Unsupervised aerobic training (50 min, 4 times per week)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (attended lectures on physical activity and health once a month)
Number of subjects: 176
Study: 20218940

Group type: EXPERIMENTAL
Intervention: Combined epidural analgesia and general anesthesia (group EA/GA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia alone (group GA)
Number of subjects: 40
Study: 16905139

Group type: EXPERIMENTAL
Intervention: High-dose lovastatin
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Low-dose lovastatin
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Low-dose warfarin
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Overall treatment effects (lovastatin and warfarin vs placebo)
Number of subjects: 1351
Study: 17315548

Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic fentanyl (TTS‐F) patches releasing 25 microg fentanyl per hour
Number of subjects: 460

Group type: COMPARATOR
Intervention: Codeine/paracetamol (120 mg per day)
Number of subjects: 460
Study: 12354129

Group type: EXPERIMENTAL
Intervention: Individualized recombinant GH substitution (0.17 mg GH/day, titrated every 6-8 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Individualized recombinant GH substitution (0.17 mg GH/day, titrated to T(max) and then reduced to T(end))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Individualized recombinant GH substitution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (17 matched control subjects)
Number of subjects: 18
Study: 9973032

Group type: EXPERIMENTAL
Intervention: Transesophageal atrial pacing stress echocardiography
Number of subjects: 104

Group type: COMPARATOR
Intervention: Dobutamine stress echocardiography
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both tests
Number of subjects: 104
Study: 7569485

Group type: EXPERIMENTAL
Intervention: Geriatric inpatient assessment and rehabilitation
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual home care
Number of subjects: 312
Study: 2299950

Group type: EXPERIMENTAL
Intervention: Blunt dissection tonsillectomy using suture ligatures for hemostasis, without postoperative antibiotics
Number of subjects: 80

Group type: COMPARATOR
Intervention: Electrocautery, dissection, KTP laser
Number of subjects: 80

Group type: COMPARATOR
Intervention: Methods of hemostasis (electrocautery, suture ligature)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Postoperative antibiotics
Number of subjects: 80
Study: 6109150

Group type: EXPERIMENTAL
Intervention: Dipyridamole (DPY), 100 mg a day and Aspirin (ASA), 1200 mg a day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dipyridamole (DPY) and Aspirin (ASA)
Number of subjects: 38
Study: 29778340

Group type: EXPERIMENTAL
Intervention: ZIPFIX sternal closure system
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard stainless steel wires
Number of subjects: 118
Study: 23475825

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (IR-methylphenidate)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 63
Study: 26205958

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Program (HeLP‐her Rural) with multiple delivery modes (group sessions, phone coaching, text messages, interactive program manual)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Face-to-face group sessions
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Text messages and phone coaching
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Overall lifestyle advice via multiple delivery modes
Number of subjects: 649
Study: 23036139

Group type: EXPERIMENTAL
Intervention: Naturopathic and nutritional supplements (NNS)
Number of subjects: 134

Group type: COMPARATOR
Intervention: No Naturopathic and nutritional supplements (NNS)
Number of subjects: 134
Study: 20584236

Group type: EXPERIMENTAL
Intervention: Strengthening Families Program (SFP) 10-14
Number of subjects: 57

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 57
Study: 19173973

Group type: EXPERIMENTAL
Intervention: Combination of lamivudine and traditional Chinese medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lamivudine alone
Number of subjects: 0
Study: 15857327

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 27
Study: 14594786

Group type: EXPERIMENTAL
Intervention: Spread A (25 g/d containing 43 mg alpha‐TE and 0.45 mg carotenoids)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Spread B (25 g/d containing 111 mg alpha‐TE and 1.24 mg carotenoids)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Spread C (25 g/d containing 1.3 mg RRR‐alpha‐tocopherol without carotenoids)
Number of subjects: 105
Study: 10847255

Group type: COMPARATOR
Intervention: Leisure time physical activity (groups 2 to 4)
Number of subjects: 30640

Group type: EXPERIMENTAL
Intervention: Sports participation
Number of subjects: 30640

Group type: EXPERIMENTAL
Intervention: Bicycling to work
Number of subjects: 30640
Study: 8853832

Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg oral dose
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1633756

Group type: EXPERIMENTAL
Intervention: Point-specific acupuncture
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sham transdermal stimulation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 56
Study: 6392119

Group type: EXPERIMENTAL
Intervention: xipamid (40 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: hydrochlorothiazide (50 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: xipamid (80 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: hydrochlorothiazide (100 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 31525156

Group type: EXPERIMENTAL
Intervention: Positive thinking training (10 sessions of 45-60 minutes over 5 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Positive thinking training
Number of subjects: 52
Study: 29764262

Group type: EXPERIMENTAL
Intervention: IgPro20 (20% IgG stabilized with L‐Proline)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Subcutaneous method
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: SCIG
Number of subjects: 172
Study: 26901268

Group type: EXPERIMENTAL
Intervention: The Coach Approach exercise‐support protocol followed by group nutrition sessions
Number of subjects: 110

Group type: COMPARATOR
Intervention: Comparison treatment with a print manual plus telephone follow‐ups
Number of subjects: 110
Study: 24722497

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Mediterranean Diet (LCMD)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Low-Fat Diet
Number of subjects: 215
Study: 22666496

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 1065
Study: 20863918

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 2 years
Number of subjects: 146

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 146

Group type: COMPARATOR
Intervention: Untreated patients with AR
Number of subjects: 146
Study: 18508833

Group type: EXPERIMENTAL
Intervention: Consecutive C-reactive protein (CRP) measurements on admission, day 3, and day 7 during follow-up of antibiotic treatment.
Number of subjects: 289
Study: 15889132

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy for 1 to 72 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Greater than 80% oxygen for more than 6 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room air controls
Number of subjects: 0
Study: 12824997

Group type: EXPERIMENTAL
Intervention: Fetal fibronectin test results known to physician
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fetal fibronectin test results not known to physician
Number of subjects: 108
Study: 11722049

Group type: EXPERIMENTAL
Intervention: Intracutaneous suture technique
Number of subjects: 300

Group type: COMPARATOR
Intervention: Percutaneous suture technique
Number of subjects: 300
Study: 9202910

Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg intravenous (i.v.)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 7960608

Group type: EXPERIMENTAL
Intervention: E (epirubicin) alone (90 mg/m2 day 1)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 5‐FU (5-Fluorouracil) alone (500 mg/m2 days 1‐5)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 5‐FU (400 mg/m2 days 1‐5) plus E (epirubicin) (90 mg/m2 day 1)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 165
Study: 3659830

Group type: EXPERIMENTAL
Intervention: Screening with Hemoccult‐II
Number of subjects: 60938

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60938
Study: 30334066

Group type: EXPERIMENTAL
Intervention: Weekly cone beam CTs (CBCT)
Number of subjects: 23
Study: 25769614

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 µg/kg/h)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23884915

Group type: EXPERIMENTAL
Intervention: Oral T4 (2 μg·kg⁻¹)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous T4 (2 μg·kg⁻¹)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral T4
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous T4
Number of subjects: 32
Study: 22043670

Group type: EXPERIMENTAL
Intervention: Acupuncture group (Back‐shu points of Five‐zang and Geshu (BL 17), Taichong (LR 3), Sanyinjiao (SP 6), Shenmen (HT 7))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medication group (Fluoxetine Hydrochloride capsule, 20 mg, once a day)
Number of subjects: 60
Study: 19171813

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study: 17002927

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15304961

Group type: EXPERIMENTAL
Intervention: 50 mg of potassium iodide (38 mg of iodide)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg of potassium iodide (76 mg of iodide)
Number of subjects: 8
Study: 10807748

Group type: EXPERIMENTAL
Intervention: TT genotype
Number of subjects: 586

Group type: COMPARATOR
Intervention: GT+GG genotypes
Number of subjects: 586
Study: 9299652

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (400 micrograms, 4 times daily for 3 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 50
Study: 8285776

Group type: EXPERIMENTAL
Intervention: Nebulised racemic adrenaline
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31819393

Group type: EXPERIMENTAL
Intervention: Oscillatory PEP (OPEP) therapy
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: PEP therapy
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: PEP ± OM therapy
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 273
Study: 29360492

Group type: EXPERIMENTAL
Intervention: Tungsten carbide bur (TC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diamond bur (Db)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Enhance PoGo discs (PG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sof‐Lex discs (S)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mylar strip (Control)
Number of subjects: 90
Study: 26988629

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 24701581

Group type: COMPARATOR
Intervention: 3MS (minimal supervision)
Number of subjects: 351

Group type: COMPARATOR
Intervention: 3WS (with supervision)
Number of subjects: 351
Study: 22878749

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 1000 mg daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 1000 mg daily plus erlotinib 150 mg
Number of subjects: 27
Study: 20972904

Group type: EXPERIMENTAL
Intervention: Chemoradiation (group A)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Chemotherapy alone (group B)
Number of subjects: 132
Study: 17097647

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) alone (100 mg/day from day 3 to day 7; n = 56)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) in combination with pure FSH (75 IU on day 3 and day 8; n = 54)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: No stimulation (n = 35)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No treatment (parous women, n = 18)
Number of subjects: 63
Study: 16275192

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 23

Group type: COMPARATOR
Intervention: Epinephrine infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: Phenylephrine bolus
Number of subjects: 23
Study: 12688625

Group type: EXPERIMENTAL
Intervention: Prophylactic group (educational package and mite allergen-impermeable mattress encasings)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 696
Study: 9950610

Group type: EXPERIMENTAL
Intervention: Normal grating acuity at age 1 year
Number of subjects: 575

Group type: COMPARATOR
Intervention: No measurable TAC grating acuity at age 1 year
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Measurable grating acuity <1.6 cyc/deg at age 1 year
Number of subjects: 575
Study: 8850659

Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 87

Group type: COMPARATOR
Intervention: PTA and stent placement
Number of subjects: 87
Study: 2407957

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (75 mg per day)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 394752

Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate 800 microgram daily
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate 400 microgram daily
Number of subjects: 95

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate 400 microgram to 800 microgram
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Number of subjects: 95
Study: 31500588

Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy
Number of subjects: 86
Study: 28780504

Group type: EXPERIMENTAL
Intervention: Intensive physical rehabilitation (90 min/day, Monday to Friday)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Standard physical rehabilitation (30 min/day, Monday to Friday)
Number of subjects: 308
Study: 26473625

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (125 mg/week)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Adalimumab (40 mg every 2 weeks)
Number of subjects: 646
Study: 25260444

Group type: EXPERIMENTAL
Intervention: Standard inguinal varicocelectomy plus oral L-carnitine therapy (250 mg 3 times a day for 6 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard inguinal varicocelectomy
Number of subjects: 100
Study: 22552034

Group type: EXPERIMENTAL
Intervention: Soy isoflavone supplementation (80 mg daily for 6 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19959293

Group type: EXPERIMENTAL
Intervention: High-frequency, high-intensity transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional pharmacological treatment (IV opioids)
Number of subjects: 200
Study: 18166126

Group type: EXPERIMENTAL
Intervention: Nystatin (nonabsorbed antifungal drug)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 16325696

Group type: EXPERIMENTAL
Intervention: JAK2 V617F mutation-positive patients
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Anagrelide therapy
Number of subjects: 806

Group type: COMPARATOR
Intervention: JAK2 V617F mutation-negative patients
Number of subjects: 806
Study: 12045085

Group type: EXPERIMENTAL
Intervention: Intramuscular droperidol 2.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular dimenhydrinate 50 mg
Number of subjects: 40
Study: 9524997

Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole vaginal gel (twice daily for 7 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oral metronidazole (250 mg, three times daily for 7 days)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole vaginal gel
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral metronidazole and 0.75% metronidazole vaginal gel
Number of subjects: 31
Study: 8585295

Group type: EXPERIMENTAL
Intervention: Calcium phosphate adsorbed vaccine
Number of subjects: 313

Group type: COMPARATOR
Intervention: Aluminium hydroxide adsorbed vaccine
Number of subjects: 313
Study: 2533896

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg t.d.s.
Number of subjects: 154

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg t.d.s.
Number of subjects: 154
Study: 773484

Group type: EXPERIMENTAL
Intervention: Intraperitoneal noxytiolin (Noxiflex) solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30949182

Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP) therapy
Number of subjects: 34
Study: 27830484

Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intramedullary nail fixation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 120